A Double-Blind, Multi-Center, Active-Controlled (15, 30, and 45mg Pioglitazone) Long Extension Study to Evaluate the Safety and Tolerability of Oral Tesaglitazar (0.5 and 1mg) in Patients with Type 2 Diabetes Melitus (Gallex 6)

Grants and Contracts Details

StatusFinished
Effective start/end date10/1/05 → 12/31/07

Funding

  • AstraZeneca Pharmaceuticals AB: $23,230.00